More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$214742239
EPS
-0.88
P/E ratio
--
Price to sales
58.13
Dividend yield
--
Beta
1.641019
Previous close
$2.09
Today's open
$2.06
Day's range
$2.03 - $2.13
52 week range
$2.02 - $3.90
show more
CEO
Andrea Pfeifer
Employees
122
Headquarters
Lausanne,
Exchange
NASDAQ Global Market
Shares outstanding
101773573
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
AC Immune to Present at Jefferies Global Healthcare Conference 2026
AC Immune to Present at Jefferies Global Healthcare Conference 2026 Lausanne, Switzerland, November 11, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharma company targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases, today announced that Martin Zügel, Interim CEO, will present and participate in a fireside chat at the annual Jefferies Global Healthcare Conference 2026, taking place November 16-19 in London, UK. The session will begin with a brief company presentation by Martin, followed by a fireside chat hosted by Alyna Shamsi, Equity Research Analyst at Jefferies.
GlobeNewsWire • Nov 11, 2026

AC Immune Third Quarter 2026 Financial and Corporate Update
AC Immune announces financial and corporate updates for the quarter ended September 30, 2026, with positive progress across its wholly-owned pipeline.
GlobeNewsWire • Nov 4, 2026

AC Immune (ACIU) Reports Q3 Loss, Beats Revenue Estimates
AC Immune (ACIU) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.2 per share a year ago.
Zacks Investment Research • Nov 4, 2026

Best Momentum Stock to Buy for September 30th
SCL and ACIU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 30, 2026.
Zacks Investment Research • Sep 30, 2026

AC Immune Parkinson's Vaccine Study Meets Safety, Immunogenicity Goals
AC Immune NASDAQ: ACIU reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson's disease.
MarketBeat • Sep 26, 2026

AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions
AC Immune maintains a "Buy" rating, driven by positive 100-week safety and immunogenicity data for ACI-7104 in early-stage Parkinson's disease. Progress in the pipeline includes Takeda-partnered ACI-24 for prodromal Alzheimer's, triggering a $12M milestone and showing antibody responses at all dose levels. Brain-penetrant NLRP3 inhibitor ACI-19764 advances, with phase 1/1b initial data at the end of 2026 and final data in the 1st half of 2027, targeting neuroinflammatory and metabolic disorders.
Seeking Alpha • Sep 24, 2026

AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizations Clear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement Discussions with FDA regarding future development path planned for early 2027 AC Immune to host webcast & conference call today at 10:00am EDT / 16:00 CEST details below Lausanne, Switzerland, September 23, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced positive safety and immunogenicity results through week-100 in Part 1 of VacSYn, its randomized, double-blind, placebo-controlled Phase 2 trial of ACI-7104 in patients with early-stage Parkinson's disease (PD). The study is being conducted in two parts with the aim for Part 1 being to show safety, tolerability and immunogenicity while Part 2 is designed to provide evidence of clinical activity as the basis for a Phase 3 decision.
GlobeNewsWire • Sep 23, 2026

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating ACI-19764, an NLRP3 inhibitor targeting inflammation.
GlobeNewsWire • Aug 20, 2026

AC Immune First Half 2026 Financial and Corporate Update
AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026 Phase 2 VacSYn trial of ACI-7104 in Parkinson's disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation Morphomer small molecule program targeting intracellular Tau progresses with Lilly Initiation of Alzheimer's disease AD4 cohort in ABATE trial triggered $12 million milestone payment from Takeda Cash resources of CHF 75.4 million as of June 30, 2026, provide funding into Q4 2027 Lausanne, Switzerland, August 5, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today provided a corporate and financial update for the half-year ended June 30, 2026. Martin Zügel, MD, interim CEO of AC Immune and Chair of the Board of Directors, commented: “AC Immune is moving towards key clinical milestones in two of our wholly-owned programs, a growing focus for AC Immune.
GlobeNewsWire • Aug 5, 2026

AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates
AC Immune (ACIU) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.25 per share a year ago.
Zacks Investment Research • Aug 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell AC Immune SA commission-free¹. Build wealth for the long term using automated trading and transfers.